Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations
← catalyst calendarSponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Basic science
Enrollment
348actual
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-10 | actual | When the study began enrolling |
| Primary completion | 2026-05-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-28 | actual | The whole study's end, after follow-up |
| First posted | 2025-11-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Overweight
- Obesity
Intervention
- Drug: Maridebart Cafraglutide — also filed as AMG 133
Primary outcomes
what the primary-completion date above is the date OFArea Under the Plasma Concentration Time Curve from Time Zero to Infinity (AUCinf) of Maridebart Cafraglutide
measured Up to Day 120
Area Under the Plasma Concentration Time Curve from Time Zero to Time of Last Quantifiable Concentration (AUClast) of Maridebart Cafraglutide
measured Up to Day 120
Maximum Observed Plasma Concentration (Cmax) of Maridebart Cafraglutide
measured Up to Day 120
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed